Patheon sells clinical packaging biz to Bellwyck

Canadian-contract manufacturer Patheon ($PTI), which has been taking steps to cut costs and reposition itself, is selling its secondary clinical packaging and clinical distribution services business to another Canadian company, Bellwyck Packaging Solutions. Terms of the deal were not disclosed. "While we don't expect the terms of the transaction to have a material impact on our ongoing results, this transaction is part of our continued focus on our core competencies of solid-dose and parenteral development and manufacturing," Patheon CEO James C. Mullen said in a release. About 20 employees will move with the business.  To boost its bottom line, Patheon last year said it would get out of semi-solids and clinical packaging and start closing facilities and consolidating operations. It put a plant in Swindon, U.K., up for sale. In May, unable to sell the plant, Patheon said it would consolidate some operations there and over two or three years stop taking on new non-cephalosporin commercial production there, finish up as much as it can and transfer the rest to other facilities. Release | More

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.